KZIA ▲ +4.6% - Kazia Therapeutics Limited $KZIA KZIA KZIA - Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer Kazia Therapeutics rose 4.6% following an announcement that the company is expanding its paxalisib clinical trial into HR+/HER2- breast cancer, supported by preclinical data demonstrating strong clinical activity and safety in this patient population. The trial expansion signals potential for the drug in a larger addressable market segment within breast cancer treatment. 01-SEP-2026 07:15 AM ET